Status:
UNKNOWN
Phenobarbital Versus Levetiracetam Neonatal Convulsion
Lead Sponsor:
Assiut University
Conditions:
Neonatal Convulsion
Eligibility:
All Genders
1-28 years
Brief Summary
If the seizure is clinically evident and prolonged, the most common first-line agent utilized is phenobarbital.(Glass et al;2016) ,Its mechanism of action is the synaptic inhibition through an action ...
Detailed Description
Neonatal seizures are a commonly encountered neurologic condition in neonates.(GlassHC; 2014) They are defined as the occurrence of sudden, paroxysmal, abnormal alteration of electrographic activity a...
Eligibility Criteria
Inclusion
- All neonates with convulsions.
Exclusion
- Convulsions that occur beyond neonatal period. 2.Secondary neonatal convulsions eg: hypoglycemic, hypocalcemic, hypomagnesemic convalsions.
Key Trial Info
Start Date :
December 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2025
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06181383
Start Date
December 30 2023
End Date
May 30 2025
Last Update
December 26 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.